Treatment With SU11248 in Patients With Neuroendocrine Tumors
NCT00056693
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
107
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Tumors
Interventions
DRUG:
Sunitinib
Sponsor
Pfizer